Growth hormone axis in chronic kidney disease

Shefali Mahesh, Frederick J. Kaskel

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) in children is associated with dramatic changes in the growth hormone (GH) and insulin-like growth factor (IGF-1) axis, resulting in growth retardation. Moderate-to-severe growth retardation in CKD is associated with increased morbidity and mortality. Renal failure is a state of GH resistance and not GH deficiency. Some mechanisms of GH resistance are: reduced density of GH receptors in target organs, impaired GH-activated post-receptor Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, and reduced levels of free IGF-1 due to increased inhibitory IGF-binding proteins (IGFBPs). Treatment with recombinant human growth hormone (rhGH) has been proven to be safe and efficacious in children with CKD. Even though rhGH has been shown to improve catch-up growth and to allow the child to achieve normal adult height, the final adult height is still significantly below the genetic target. Growth retardation may persist after renal transplantation due to multiple factors, such as steroid use, decreased renal function and an abnormal GH-IGF1 axis. Those below age 6 years are the ones to benefit most from transplantation in demonstrating acceleration in linear growth. Newer treatment modalities targeting the GH resistance with recombinant human IGF-1 (rhIGF-1), recombinant human IGFBP3 (rhIGFBP3) and IGFBP displacers are under investigation and may prove to be more effective in treating growth failure in CKD.

Original languageEnglish (US)
Pages (from-to)41-48
Number of pages8
JournalPediatric Nephrology
Volume23
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Chronic Renal Insufficiency
Growth Hormone
Growth
Insulin-Like Growth Factor I
Insulin-Like Growth Factor Binding Proteins
Human Growth Hormone
Janus Kinases
Somatotropin Receptors
Somatomedins
Transducers
Kidney Transplantation
Renal Insufficiency
Transplantation
Steroids
Morbidity
Kidney
Mortality
Therapeutics

Keywords

  • Chronic kidney failure
  • Growth failure
  • Growth hormone
  • Insulin-likegrowth factor
  • Treatment

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Growth hormone axis in chronic kidney disease. / Mahesh, Shefali; Kaskel, Frederick J.

In: Pediatric Nephrology, Vol. 23, No. 1, 01.2008, p. 41-48.

Research output: Contribution to journalArticle

Mahesh, Shefali ; Kaskel, Frederick J. / Growth hormone axis in chronic kidney disease. In: Pediatric Nephrology. 2008 ; Vol. 23, No. 1. pp. 41-48.
@article{7e3864b2f23640ae893ceaa75f04f047,
title = "Growth hormone axis in chronic kidney disease",
abstract = "Chronic kidney disease (CKD) in children is associated with dramatic changes in the growth hormone (GH) and insulin-like growth factor (IGF-1) axis, resulting in growth retardation. Moderate-to-severe growth retardation in CKD is associated with increased morbidity and mortality. Renal failure is a state of GH resistance and not GH deficiency. Some mechanisms of GH resistance are: reduced density of GH receptors in target organs, impaired GH-activated post-receptor Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, and reduced levels of free IGF-1 due to increased inhibitory IGF-binding proteins (IGFBPs). Treatment with recombinant human growth hormone (rhGH) has been proven to be safe and efficacious in children with CKD. Even though rhGH has been shown to improve catch-up growth and to allow the child to achieve normal adult height, the final adult height is still significantly below the genetic target. Growth retardation may persist after renal transplantation due to multiple factors, such as steroid use, decreased renal function and an abnormal GH-IGF1 axis. Those below age 6 years are the ones to benefit most from transplantation in demonstrating acceleration in linear growth. Newer treatment modalities targeting the GH resistance with recombinant human IGF-1 (rhIGF-1), recombinant human IGFBP3 (rhIGFBP3) and IGFBP displacers are under investigation and may prove to be more effective in treating growth failure in CKD.",
keywords = "Chronic kidney failure, Growth failure, Growth hormone, Insulin-likegrowth factor, Treatment",
author = "Shefali Mahesh and Kaskel, {Frederick J.}",
year = "2008",
month = "1",
doi = "10.1007/s00467-007-0527-x",
language = "English (US)",
volume = "23",
pages = "41--48",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Growth hormone axis in chronic kidney disease

AU - Mahesh, Shefali

AU - Kaskel, Frederick J.

PY - 2008/1

Y1 - 2008/1

N2 - Chronic kidney disease (CKD) in children is associated with dramatic changes in the growth hormone (GH) and insulin-like growth factor (IGF-1) axis, resulting in growth retardation. Moderate-to-severe growth retardation in CKD is associated with increased morbidity and mortality. Renal failure is a state of GH resistance and not GH deficiency. Some mechanisms of GH resistance are: reduced density of GH receptors in target organs, impaired GH-activated post-receptor Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, and reduced levels of free IGF-1 due to increased inhibitory IGF-binding proteins (IGFBPs). Treatment with recombinant human growth hormone (rhGH) has been proven to be safe and efficacious in children with CKD. Even though rhGH has been shown to improve catch-up growth and to allow the child to achieve normal adult height, the final adult height is still significantly below the genetic target. Growth retardation may persist after renal transplantation due to multiple factors, such as steroid use, decreased renal function and an abnormal GH-IGF1 axis. Those below age 6 years are the ones to benefit most from transplantation in demonstrating acceleration in linear growth. Newer treatment modalities targeting the GH resistance with recombinant human IGF-1 (rhIGF-1), recombinant human IGFBP3 (rhIGFBP3) and IGFBP displacers are under investigation and may prove to be more effective in treating growth failure in CKD.

AB - Chronic kidney disease (CKD) in children is associated with dramatic changes in the growth hormone (GH) and insulin-like growth factor (IGF-1) axis, resulting in growth retardation. Moderate-to-severe growth retardation in CKD is associated with increased morbidity and mortality. Renal failure is a state of GH resistance and not GH deficiency. Some mechanisms of GH resistance are: reduced density of GH receptors in target organs, impaired GH-activated post-receptor Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, and reduced levels of free IGF-1 due to increased inhibitory IGF-binding proteins (IGFBPs). Treatment with recombinant human growth hormone (rhGH) has been proven to be safe and efficacious in children with CKD. Even though rhGH has been shown to improve catch-up growth and to allow the child to achieve normal adult height, the final adult height is still significantly below the genetic target. Growth retardation may persist after renal transplantation due to multiple factors, such as steroid use, decreased renal function and an abnormal GH-IGF1 axis. Those below age 6 years are the ones to benefit most from transplantation in demonstrating acceleration in linear growth. Newer treatment modalities targeting the GH resistance with recombinant human IGF-1 (rhIGF-1), recombinant human IGFBP3 (rhIGFBP3) and IGFBP displacers are under investigation and may prove to be more effective in treating growth failure in CKD.

KW - Chronic kidney failure

KW - Growth failure

KW - Growth hormone

KW - Insulin-likegrowth factor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=37049036873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049036873&partnerID=8YFLogxK

U2 - 10.1007/s00467-007-0527-x

DO - 10.1007/s00467-007-0527-x

M3 - Article

VL - 23

SP - 41

EP - 48

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 1

ER -